O. Arén Frontera

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

L. Crinò, J. Aerts, E. Vokes, 2015, The New England journal of medicine.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

A. Ravaud, S. Signoretti, R. Motzer, 2020, Clinical Cancer Research.

Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America

A. Cardona, L. Raez, A. Avilés-Salas, 2018, Oncology.

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

C. Porta, A. Ravaud, R. Motzer, 2020, Journal for ImmunoTherapy of Cancer.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

C. Porta, R. Motzer, T. Powles, 2019, The Lancet. Oncology.

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

R. Motzer, T. Powles, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

L. Urban, E. Felip, Han Chang, 2023, Journal for ImmunoTherapy of Cancer.